Efficacy of polyunsaturated fatty acids on inflammatory markers in patients undergoing dialysis: A systematic review with network meta-analysis of randomized clinical trials

Po Kuan Wu, Shu Ching Yeh, Shan Jen Li, Yi No Kang

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The effects of polyunsaturated fatty acids (PUFAs) on inflammatory markers among patients receiving dialysis have been discussed for a long time, but previous syntheses made controversial conclusion because of highly conceptual heterogeneity in their synthesis. Thus, to further understanding of this topic, we comprehensively gathered relevant randomized clinical trials (RCTs) before April 2019, and two authors independently extracted data of C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) for conducting network meta-analysis. Eighteen eligible RCTs with 962 patients undergoing dialysis were included in our study. The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): −0.37, 95% confidence interval (CI): −0.07 to −0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Although no significant changes were noted for hs-CRP and IL-6 levels, PUFAs showed the best ranking among treatments according to surface under the cumulative ranking. Therefore, PUFAs could be a protective option for patients receiving dialysis in clinical practice.

Original languageEnglish
Article number3645
JournalInternational Journal of Molecular Sciences
Volume20
Issue number15
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Polyunsaturated fatty acids
dialysis
Dialysis
fatty acids
Unsaturated Fatty Acids
markers
C-Reactive Protein
Randomized Controlled Trials
proteins
Proteins
interleukins
tocopherol
ranking
Vitamins
Vitamin E
Interleukin-6
sensitivity
synthesis
Network Meta-Analysis
confidence

Keywords

  • C-reactive protein
  • Inflammatory maker
  • Interleukin-6
  • Omega-3 fatty acid
  • Polyunsaturated fatty acids

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

@article{fa362889936543728efcf5fa0df79acb,
title = "Efficacy of polyunsaturated fatty acids on inflammatory markers in patients undergoing dialysis: A systematic review with network meta-analysis of randomized clinical trials",
abstract = "The effects of polyunsaturated fatty acids (PUFAs) on inflammatory markers among patients receiving dialysis have been discussed for a long time, but previous syntheses made controversial conclusion because of highly conceptual heterogeneity in their synthesis. Thus, to further understanding of this topic, we comprehensively gathered relevant randomized clinical trials (RCTs) before April 2019, and two authors independently extracted data of C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) for conducting network meta-analysis. Eighteen eligible RCTs with 962 patients undergoing dialysis were included in our study. The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): −0.37, 95{\%} confidence interval (CI): −0.07 to −0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Although no significant changes were noted for hs-CRP and IL-6 levels, PUFAs showed the best ranking among treatments according to surface under the cumulative ranking. Therefore, PUFAs could be a protective option for patients receiving dialysis in clinical practice.",
keywords = "C-reactive protein, Inflammatory maker, Interleukin-6, Omega-3 fatty acid, Polyunsaturated fatty acids",
author = "Wu, {Po Kuan} and Yeh, {Shu Ching} and Li, {Shan Jen} and Kang, {Yi No}",
year = "2019",
month = "8",
day = "1",
doi = "10.3390/ijms20153645",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "15",

}

TY - JOUR

T1 - Efficacy of polyunsaturated fatty acids on inflammatory markers in patients undergoing dialysis

T2 - A systematic review with network meta-analysis of randomized clinical trials

AU - Wu, Po Kuan

AU - Yeh, Shu Ching

AU - Li, Shan Jen

AU - Kang, Yi No

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The effects of polyunsaturated fatty acids (PUFAs) on inflammatory markers among patients receiving dialysis have been discussed for a long time, but previous syntheses made controversial conclusion because of highly conceptual heterogeneity in their synthesis. Thus, to further understanding of this topic, we comprehensively gathered relevant randomized clinical trials (RCTs) before April 2019, and two authors independently extracted data of C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) for conducting network meta-analysis. Eighteen eligible RCTs with 962 patients undergoing dialysis were included in our study. The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): −0.37, 95% confidence interval (CI): −0.07 to −0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Although no significant changes were noted for hs-CRP and IL-6 levels, PUFAs showed the best ranking among treatments according to surface under the cumulative ranking. Therefore, PUFAs could be a protective option for patients receiving dialysis in clinical practice.

AB - The effects of polyunsaturated fatty acids (PUFAs) on inflammatory markers among patients receiving dialysis have been discussed for a long time, but previous syntheses made controversial conclusion because of highly conceptual heterogeneity in their synthesis. Thus, to further understanding of this topic, we comprehensively gathered relevant randomized clinical trials (RCTs) before April 2019, and two authors independently extracted data of C-reactive protein (CRP), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) for conducting network meta-analysis. Eighteen eligible RCTs with 962 patients undergoing dialysis were included in our study. The result showed that with placebo as the reference, PUFAs was the only treatment showing significantly lower CRP (weighted mean difference (WMD): −0.37, 95% confidence interval (CI): −0.07 to −0.68), but the CRP in PUFAs group was not significantly lower than vitamin E, PUFAs plus vitamin E, or medium-chain triglyceride. Although no significant changes were noted for hs-CRP and IL-6 levels, PUFAs showed the best ranking among treatments according to surface under the cumulative ranking. Therefore, PUFAs could be a protective option for patients receiving dialysis in clinical practice.

KW - C-reactive protein

KW - Inflammatory maker

KW - Interleukin-6

KW - Omega-3 fatty acid

KW - Polyunsaturated fatty acids

UR - http://www.scopus.com/inward/record.url?scp=85070678013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070678013&partnerID=8YFLogxK

U2 - 10.3390/ijms20153645

DO - 10.3390/ijms20153645

M3 - Review article

C2 - 31349671

AN - SCOPUS:85070678013

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 15

M1 - 3645

ER -